FDA Grants Fast Track Designation to ARCA biopharma’s Potential COVID-19 Treatment
FDA granted fast track designation for AB201, a small recombinant protein that is a potent, selective inhibitor of tissue factor, for the potential treatment of COVID-19.
On Nov. 23, 2020, ARCA biopharma, a US-based biopharmaceutical company specializing in a precision-medicine approach to developing cardiovascular therapeutics, announced that FDA has granted fast track designation for its investigational compound, AB201, a small recombinant fusion protein, for the potential treatment of COVID-19.
The company plans to initiate a Phase IIb clinical trial in December 2020 of the compound in approximately 100 patients hospitalized with COVID-19, with topline trial data anticipated in the second quarter of 2021. AB201 is a potent, selective inhibitor of tissue factor (TF), which plays a central role in the inflammatory response to viral infections.
“Fast [t]rack designation for the AB201 development program is an important acknowledgement of the critical need for treatments for hospitalized COVID-19 patients, whether effective vaccines are approved and available or not,” said Dr. Michael Bristow, ARCA’s president and CEO, in a company press release. “We believe AB201’s combination of anticoagulant, anti-inflammatory, and antiviral effects may favorably impact clinical recovery of patients hospitalized with COVID-19 and look forward to beginning the ASPEN-COVID-19 trial to evaluate AB201’s potential efficacy in this patient population.”
Source: ARCA biopharma
Benuvia Granted GMP Certification by Brazil National Health Surveillance Agency
March 14th 2025The certification allows Benuvia to produce pharmaceutical products for companies, either local to Brazil or international, that may be looking for compliant and high-quality production capabilities in the Brazilian pharmaceutical market.
